EQS-News: Defence Therapeutics Inc.
/ Key word(s): Miscellaneous
_________________________________________________________________ CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE THERAPEUTICS GRANTED CNRI-H FROM THE CANADIAN NUCLEAR LABORATORIES TO ACCELERATE THE DEVELOPMENT OF ITS RADIO-IMMUNO-CONJUGATES PROGRAM
Vancouver, BC, Canada, July 24th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its Canadian Nuclear Research Initiative Health (“CNRI-H”) Program application was retained and approved by the Canadian Nuclear Laboratories (“CNL”) to accelerate Defence’s radio-immuno-conjugates project.
Defence’s CNRI-H project will focus on the synthesis and evaluation of novel constructs, variations of 111In-AccuTOX®-Trastuzumab. The objective is to demonstrate that AccuTOX® moiety is an essential modification to conventional 111In-Trastuzumab constructs to evade an endosome entrapment and ensure nuclear localization, where 111In will emit Auger Electrons (“AEs”) to kill cancer cells, and providing a synergistic effect by unleashing AccuTOX® immune-boosting power. It is expected that these constructs will be lethal to HER2-positive cancer cells specifically and will produce high potency.
Selected AccuTOX® constructs, based on stability, solubility, and biochemical properties, will be conjugated to the trastuzumab antibody, followed by radiolabeled with 111In, and then characterized, in vitro and in vivo, for its efficacy in killing cancer. The main goal is to identify the biologically active 111In-AccuTOX®-Trastuzumab molecule that will be more potent to treat solid tumor resistant to current HER2-targeting therapy such as therapeutic antibodies (e.g., trastuzumab alone) and antibody-drug conjugate (e.g., Kadcyla®). In summary, the aim of this CNRI-H collaborative project is: 1. To synthesize AccuTOX®-Trastuzumab antibody conjugates, radiolabel with 111In, and characterize, including structure and cellular analysis (e.g. identification, drug-antibody ratio, specific activity), stability, and cytotoxic effects, in vitro. 2. To perform animal studies in rodents, in vivo, namely biodistribution, pharmacokinetic profile, and therapeutic potency, using selected 111In-AccuTOX®-Trastuzumab constructs.
“We are proud to have this opportunity to collaborate with the Canadian Nuclear Laboratories and to advancing Defence’s radio-immuno-conjugates program for the benefit of the cancer’s patients. The CNL scientific team dedicated to our project is very strong and will definitely accelerate and reinforce Defence’s strength in this renowned and fast-growing radiopharmaceuticals field,” said Sebastien Plouffe, Chief Executive Officer of Defence Therapeutics.
According to Allied Market Research, the global radiopharmaceuticals market was valued at $7.9 billion in 2023, and is projected to reach $21.8 billion by 2033, growing at a CAGR of 10.6% from 2024 to 2033. And according to Straits Research, the global radioligand therapy market size was valued at USD 12.55 billion in 2023, and it is anticipated to reach USD 21.55 billion by 2032 with a CAGR of 4.62%. The use of radioligands to treat specific cancers is a novel method. It delivers radiation to cancer cells with pinpoint accuracy and minimal side effects on healthy cells, resulting in higher treatment efficacy. https://www.alliedmarketresearch.com/radiopharmaceuticals-market-A14458 https://straitsresearch.com/report/radioligand-therapy-market
About Defence: Defence Therapeutics is a publicly-traded clinical-stage biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of vaccine antigens or ADCs inside target cells and favoring their processing and activities. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information: Sebastien Plouffe, President, CEO and Director P: (514) 947-2272 Splouffe@defencetherapeutics.com
Cautionary Statement Regarding “Forward-Looking” Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
24.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Defence Therapeutics Inc. |
1680 - 200 Burrard St | |
V6C3L6 Vancouver | |
Canada | |
E-mail: | info@defencetherapeutics.com |
Internet: | https://defencetherapeutics.com |
ISIN: | CA24463V1013 |
WKN: | A3CN14 |
Listed: | Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto |
EQS News ID: | 1952507 |
End of News | EQS News Service |
|
1952507 24.07.2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.